Biogen Inc. shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and...
Biogen Inc.
shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer’s treatment it makes with Eisai Co. Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88. Eisai shares finished Friday up 9.4% at $81.03. On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend the companies’ drug Leqembi to treat Alzheimer’s disease. While the FDA is not bound to committee... Biogen Inc.
shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer’s treatment it makes with Eisai Co. Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88. Eisai shares finished Friday up 9.4% at $81.03. On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously to recommend the companies’ drug Leqembi to treat Alzheimer’s disease. While the FDA is not bound to committee recommendations, the agency generally follows them. Approval of the drug is expected by July 6.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Eisai-Biogen Alzheimer's Drug Data Confirms Benefits: FDAUS Food and Drug Administration staff on Wednesday said data from a late-stage trial of Eisai and Biogen's Alzheimer's disease drug suggests it offered a meaningful benefit to patients.
Leer más »
FDA panel weighs US approval for Alzheimer's drug from Eisai and BiogenA panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.
Leer más »
FDA advisers vote in favor of Biogen and Eisai's collaborative Alzheimer's treatmentIf granted full FDA approval, which could come in early July, treatment could boost annual Medicare spending by nearly $9 billion, analysis shows.
Leer más »
US FDA panel backs approval for Eisai-Biogen Alzheimer's drug LeqembiExpected FDA approval would make Leqembi the first in its class of drugs that work by removing sticky amyloid plaques from the brain to achieve the regulatory milestone.
Leer más »
Marvel To Launch Avengers Inc, From Al Ewing & Leonard KirkWe've had a Batman Inc. We've had a Joker Inc. Now, we have Avengers, Inc. But looking a bit more like the British TV show...
Leer más »
Alzheimer’s advocates rally for Medicare coverage of newly approved FDA treatmentsNew treatments for Alzheimer’s are on the market, but the price tag is making them inaccessible. The new treatments are not covered by Medicare or Medicaid, which is something the Alzheimer’s Association is trying to change.
Leer más »